Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-05-10
2011-05-10
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S322000, C514S403000, C546S199000, C548S361500
Reexamination Certificate
active
07939520
ABSTRACT:
The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.
REFERENCES:
patent: 6380199 (2002-04-01), Reavill et al.
patent: WO 2004/074243 (2004-09-01), None
patent: WO 2007/032833 (2007-02-01), None
Bentley, J.C. et al. “Investigation of stretching behaviour induced by the selective 5-HT6 receptor antagonist, Ro 04-6790, in rats.” Br J Pharmacol. 1999; 126(7):1537-42.
Branchek, T.A. et al. “5-HT6 receptors as emerging targets for drug discovery”. Annu Rev Pharmacol Toxicol. 2000; 40:319-3.
Dawson L.A., et al. “In vivo effects of the 5-HT6 antagonist SB-271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5-HT, glutamate and aspartate.” Br J Pharmacol. 2000; 130(1):23-6.
Ernst, M. et al. “DOPA decarboxylase activity in attention deficit hyperactivity disorder adults. A [fluorine-18]fluorodopa positron emission tomographic study.” J Neurosci. 1998; 18(15):5901-7.
Kohen, R. et al. “Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor.” J Neurochem. 1996; 66(1):47-56.
Lowry et al. “Protein measurement with the Folin phenol reagent.” J Biol Chem. 1951;193(1):265-75.
Gerard, C. et al. “Immuno-localization of serotonin 5-HT6 receptor-like material in the rat central nervous system”. Brain Res. 1997; 746(1-2):207-19.
Monsma, F. J. et al. “Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs.” Mol Pharmacol. 1993; 43(3):320-7.
Reavill, C. et al. “The therapeutic potential of 5-HT6 receptor antagonists”. Curr Opin Investig Drugs. 2001; 2(1):104-9.
Rogers, D. C. et al. “The selective 5HT6 receptor antagonist, sb-271046-a, enhances performance of maze tasks in the rat.” Society of Neuroscience, Abstracts, 2000.
Routledge,C. et al. “Characterization of SB-271046: a potent, selective and orally active 5-HT6 receptor antagonist.” Br J Pharmacol. 2000; 130(7):1606-12.
Ruat, M. et al. “A novel rat serotonin (5-HT6) receptor: molecular cloning, localization and stimulation of cAMP accumulation”. Biochem Biophys Res Commun. 1993;193(1):268-76.
Ward, R.P. et al. “Localization of serotonin subtype 6 receptor messenger RNA in the rat brain by in situ hybridization histochemistry.” Neuroscience. 1995; 64(4):1105-11.
Woolley, M.L. et al. “Reversal of a cholinergic-induced deficit in a rodent model of recognition memory by the selective 5-HT6 receptor antagonist, Ro 04-6790.” Psychopharmacology (Berl). 2003; 170(4):358-67.
Schreiber, R., et al., “5-HT6Receptors as Targets for the Treatment of Cognitive Deficits in Schizophrenia”, The Receptors: The Serotonin Receptors, 2006, pp. 495-515, Appendix A.
Holenz, J., et al., “Medicinal Chemistry Strategies to 5-HT6Receptor Ligands as Potential Cognitive Enhancer and Antiobesity Agents”, Drug Discovery Today, 2006, pp. 283-299, vol. 11, Appendix 2.
Ernst, M., et al., “DOPA Decarboxylase Activity in Attention Deficit Hyperactivity Disorder Adults. A [Fluorine-18]Fluorodopa Positron Emission Tomographic Study”, The Journal of Neuroscience, 1998, pp. 5901-5907, vol. 18,Appendix 4.
Mitchell, E., et al., “5-HT6Receptors: A Novel Target for Cognitive Enhancements”, Pharmacology & Therapeutics, 2005, pp. 320-333, vol. 108, Appendix 5.
Schechter, L. E., et al., “Neuropharmacological Profile of Novel and Selective 5-HT6Receptor Agonists: WAY-181187 and WAY-208466”, Neuropsychopharmacology, 2008, pp. 1323-1335, vol. 33, Appendix 6.
Messina, et al., “Association of the 5-HT6Receptor Gene Polymorphism C267T with Parkinson's Disease”, Neurology, 2002, pp. 828-829, vol. 58, Appendix 7.
Routledge, C., et al., “Characterization of SB-271046: A Potent, Selective and Orally Active 5-HT6Receptor Antagonist”, British Journal of Pharmacology, 2000, pp. 1606-1612, vol. 130, Appendix 8.
Pullagurla, M., et al., “Modulation of the Stimulus Effects of (+) amphetamine by the 5-HT6 Antagonist MS-245”, Pharmacology, Biochemistry and Behavior, 2004, pp. 263-268, vol. 78, Appendix 9.
Andrae Patrick
Haydar Simon Nicolas
Kispert Jennifer A.
Saeed Kamal A
Wyeth LLC
Zanzalari Richard V.
LandOfFree
Aminoazacyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aminoazacyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aminoazacyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2625158